Effects of oral combined hormone replacement therapy on plasma lipids and lipoproteins

Metabolism: Clinical and Experimental

Volumn 47, Issue 10, 1998, Pages 1222-1226

  Vadlamudi, Satyaprasad ^b   MacLean, Paul ^b   Israel, R Gay ^b   Marks, Richard H ^b   Mickey, Matthew ^b   Otvos, James ^b   Barakat, Hisham ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTROGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN; MEDROXYPROGESTERONE; PROGESTERONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CHOLESTEROL TRANSPORT; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY RISK; ENZYME ACTIVITY; ESTROGEN THERAPY; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MENOPAUSE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RISK MANAGEMENT;

EID: 0031721078     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(98)90327-4     Document Type: Article

References (34)

1. Campos H, McNamara JR, Wilson PW, et al: Differences in low density lipoprotein subfractions and apolipoproteins in premenopausal and postmenopausal women. J Clin Endocrinol Metab 67:30-35, 1988
2. Jensen J, Nilas L, Christiansen C: Influence of menopause on serum lipids and lipoproteins. Maturitas 12:321-331, 1990
3. Rudel LL, Parks JS, Johnson FL, et al: Low density lipoproteins in atherosclerosis. J Lipid Res 27:465-474, 1986
4. Austin MA, Breslow JL, Hennekens CH, et al: Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 260:1917-1921, 1988
5. Campos H, Genest JJ Jr, Blijlevens E, et al: Low density lipoprotein particle size and coronary artery disease. Arterioscler Thromb 12:187-195, 1992
6. Griffin BA, Freeman DJ, Taait GW, et al: Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: Relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis 106:241-253, 1994
7. Stampfer MJ, Krauss RM, Ma J, et al: A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 276:882-888, 1996
8. Gardner CD, Fortmann SP, Krauss RM: Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA 276:875-881, 1996
9. de Graaf J, Hak-Lemmers HLM, Hectors MPC, et al: Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler Thromb 11:298-306, 1991
10. Tribble DL, van den Berg JJ, Motchnik PA, et al: Oxidative susceptibility of low density lipoprotein subfractions is related to their ubiquinol-10 and alpha-tocopherol content. Proc Natl Acad Sci USA 91:1183-1187, 1994
11. Nordestgaard BG, Nielsen LB: Atherosclerosis and arterial influx of lipoproteins. Curr Opin Lipidol 4:252-257, 1994
12. Kinoshita M, Krul ES, Schonfeld G: Modification of the core lipids of low density lipoproteins produces selective alterations in the expression of apoB-100 epitopes. J Lipid Res 31:701-708, 1990
13. Kleinman Y, Schonfeld G, Gavish D, et al: Hypolipidemic therapy modulates expression of apolipoprotein B epitopes on low density lipoproteins. Studies in mild to moderate hypertriglyceridemic patients. J Lipid Res 28:540-548, 1987
14. Feingold KR, Grunfeld C, Pang M, et al: LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes. Arterioscler Thromb 12:1496-1502, 1992
15. Li Z, McNamara JR, Fruchart J-C, et al: Effects of gender and menopausal status on plasma lipoprotein subspecies and particle sizes. J Lipid Res 37:1886-1896, 1996
16. Barrett-Connor E, Miller V: Estrogens, lipids, and heart disease. Clin Geriatr Med 9:57-67, 1993
17. Walsh BW, Schiff I, Rosner B, et al: Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 325:1196-1204, 1991
18. Rajman I, Lip GY, Cramb R, et al: Adverse changes in low-density lipoprotein subfractions profile with oestrogen-only hormone replacement therapy. Q J Med 89:771-778, 1996
19. Tilly-Kiesi M, Puolakka LJ, Luotola H, et al: Different effects of continuous oestrogen-progestin and transdermal oestrogen with cyclic progestin regimens on low-density lipoprotein subclasses. Eur J Clin Invest 26:1125-1133, 1996
20. Wilmore JA, Vodak P, Parr R, et al: Further simplification of a method for determination of residual lung volume. Med Sci Sports Exerc 12:216-218, 1980
21. Siri WE: Body composition from fluid spaces, in Brozek J, Henschel A (eds): Techniques for Measuring Body Composition. Washington, DC, National Academy of Science, 1961, pp 223-244
22. Houmard JA, Wheeler WS, McCammon MR, et al: An evaluation of waist to hip ratio measurement methods in relation to lipid and carbohydrate metabolism in men. Int J Obes 15:181-188, 1990
23. Shireman RB, Durieux J: Microplate methods for determination of serum cholesterol, high density lipoprotein cholesterol, triglyceride and apolipoproteins. Lipids 28:151-155, 1993
24. Otvos JD: Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy, in Handbook of Lipoprotein Testing. Washington, DC, AACC, 1997, pp 497-508
25. Tilly-Kiesi M, Knudsen P, Groop L, et al: Hyperinsulinemia and insulin resistance are associated with multiple abnormalities of lipoprotein subclasses in glucose-tolerant relatives of NIDDM patients. Botnia Study Group. J Lipid Res 37:1569-1578, 1996
26. Peeples LH, Carpenter JW, Israel RG, et al: Alterations in low density lipoproteins in subjects with abdominal adiposity. Metabolism 38:1029-1036, 1989
27. Barakat HA, Carpenter JW, McLendon VD, et al: Influence of obesity, impaired glucose tolerance, and NIDDM on LDL structure and composition. Diabetes 39:1527-1533, 1990
28. Tall A, Granot E, Brocia R, et al: Accelerated transfer of cholesteryl esters in dyslipidemic plasma. Role of cholesteryl ester transfer protein. J Clin Invest 79:1217-1225, 1987
29. Tollefson JH, Albers JJ: Isolation, characterization, and assay of lipid transfer proteins. Methods Enzymol 129:797-816, 1986
30. The Writing Group for the PEPI Trial: Effects of estrogen or estrogen-progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial period. JAMA 272:199-208, 1995
31. Moorjani S, Dupont A, Labrie F, et al: Changes in plasma lipoprotein and apolipoprotein composition in relation to oral versus percutaneous administration of estrogen alone or in cyclic association with utrogestan in menopausal women. J Clin Endocrinol Metab 73:373-379, 1991
32. van der Mooren MJ, de Graaf J, Demacker PNM, et al: Changes in the low-density lipoprotein profile during 17β-estradiol-dydrogesterone therapy in postmenopausal women. Metabolism 43:799-802, 1994
33. Omu AE, Al-Qattan N: Effect of postmenopausal estrogen replacement therapy on lipoproteins. Int J Gynecol Obstet 52:155-161, 1996
34. Walsh BW, Li H, Sacks FM: Effects of postmenopausal hormone replacement with oral and transdermal estrogen on high density lipoprotein metabolism. J Lipid Res 35:2083-2093, 1994